



Stefan Diem

attending physician

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Stefan Diem
Switzerland

T +41 71 494 7239
stefan.diem@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Profile Function

attending physician

Publications (35)

Purde M, Semela D, Risch L, Früh M, Lenz T, Niederhauser C, Risch M, Joerger M, Bergamin I, Hillmann D, Hasan Ali O, Berner F, Diem S, Wagner N, Niederer R, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. *J Cancer Res Clin Oncol* 2021; 148:647-656.

Herbrand A, Hemkens L, Novak U, Moffa G, Joerger M, Hoogkamer A, Diem S, Goldkuhle M, Ewald H, Briel M, Schmitt A, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. *JAMA Netw Open* 2021; 4:e210380.

Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühn K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer* 2021; 9

Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. *J Cancer Res Ther* 2021; 17:276-278.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Favara D, Larkin J, Powell N, Turajlic S, Chauhan D, Diem S, Daniels E, Clark J, Au L, Spain L, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. *ESMO Open* 2020; 5

Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Joerger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. *ESMO Open* 2019; 4:e000596.

Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2019; 82:854-861.

Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludwig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019; 5:1043-1047.

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludwig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Hasan Ali O, Lenz T, Driessen C, Früh M, Joerger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. *Eur J Cancer* 2018; 107:8-14.

Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. *Cancer Manag Res* 2018; 10:5537-5544.

Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). *Cancer Immunol Immunother* 2018

Safroneeva E, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer A, Netzer P, Juillerat P, Saner C, Rossel J, Golay D, Pittet V, Godat S, Diem S, Aepli P, Sauter R, Borovicka J, Burgmann K, Swiss EoE Cohort Study Group. Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECs). *Inflamm Intest Dis* 2018; 2:163-170.

Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. *Cancer Immunol Immunother* 2017; 67:39-45.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.

Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. *Hematol Oncol* 2017

Morganstein D, Lai Z, Spain L, Diem S, Levine D, Mace C, Gore M, Larkin J. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. *Clin Endocrinol (Oxf)* 2017; 86:614-620.

Diem S. Thyroid Abnormalities following the use of CTLA-4 and PD-1 Inhibitors in the treatment of melanoma. *Clinical endocrinology* 2016

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415-417.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Bowyer S, Liniker E, Guminski A, Parente P, Andrews M, Parakh S, Cebon J, Long G, Carlino M, Kong B, Ramanujam S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Klein O. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. *Br J Cancer* 2016; 114:1084-9.

Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. *Cancer Treat Rev* 2016; 44:51-60.

Diem S, Kasenda B, Spain L, Martin-Liberal J, Marconcini R, Gore M, Larkin J. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. *Br J Cancer* 2016; 114:256-61.

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. *J Immunother* 2016; 39:379-382.

Diem S. Prognostic score for patients with advanced melanoma treated with ipilimumab. *European Journal of Cancer* 2015

Richman J, Martin-Liberal J, Diem S, Larkin J. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. *Expert Opin Pharmacother* 2015; 16:1285-97.

Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. *Eur J Intern Med* 2014; 25:577-82.

Diem S. Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis. *European Journal of Internal Medicine* 2014

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, Cerny T. Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study. *Eur J Clin Pharmacol* 2014; 70:719-25.

Diem S. Off-Label use of anti-cancer drugs in Switzerland: A population based prospective cohort study. *European journal of clinical pharmacology* 2014

Hitz F, Diem S, Haile S, Ess S, Cerny T, Mey U. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. *Hematol Oncol* 2013

Diem S. Outcome of mantle cell lymphoma patients treated at a single institution over the past decade. *Hematological oncology* 2013

Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. *Case Rep Oncol* 2013; 6:316-9.

Projects (4)

Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)

Clinical Studies - Jul 15, 2016 - Oct 15, 2019

Automatically Closed

A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Plati-num sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line

Clinical Studies - May 27, 2014 - Jun 27, 2016

Automatically Closed

A Phase I and stratified, multicenter Phase II trial of trans-dermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer

Clinical Studies - Apr 14, 2014 - Jul 23, 2017

Automatically Closed

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with KRAS- and BRAF wild-type metastatic colorectal cancer. A multicenter phase II trial, Leit-EK Zürich

Clinical Studies - Jan 10, 2013 - Sep 27, 2022

Aborted

Kantonsspital St.Gallen
Rorschacher Strasse 95
CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch